{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:13Z","timestamp":1792806133273,"version":"4.5.0"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04401-w","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T17:10:33Z","timestamp":1780765833000},"page":"5084-5102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-recurrence management of malignant glial brain tumors: therapeutic strategies, evidence and limitations, palliative care, terminal sedation, and end-of-life considerations"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7129-3109","authenticated-orcid":false,"given":"Eva Mar\u00eda","family":"Corrales-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-6958","authenticated-orcid":false,"given":"Pedro David","family":"Delgado-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3548-9961","authenticated-orcid":false,"given":"Juan Manuel","family":"Sep\u00falveda S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8558-015X","authenticated-orcid":false,"given":"Roberto","family":"Garcia Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4733-6921","authenticated-orcid":false,"given":"Gonzalo","family":"Lend\u00ednez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4756-7031","authenticated-orcid":false,"given":"Santiago","family":"Cabezas-Camarero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3764-4362","authenticated-orcid":false,"given":"Mar\u00eda","family":"S\u00e1nchez-Isac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1522-4495","authenticated-orcid":false,"given":"Mar\u00eda","family":"Hern\u00e1ndez Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Ruiz Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Carrillo Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7298-9060","authenticated-orcid":false,"given":"Jer\u00f3nimo","family":"Gonz\u00e1lez Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"17","key":"4401_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174279","volume":"15","author":"MA Vaz-Salgado","year":"2023","unstructured":"Vaz-Salgado MA, Villamayor M, Albarr\u00e1n V, Al\u00eda V, Sotoca P, Chamorro J, et al. Recurrent glioblastoma: a review of the treatment options. Cancers (Basel). 2023;15(17):4279. https:\/\/doi.org\/10.3390\/cancers15174279.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4401_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081927","volume":"10","author":"A Leone","year":"2022","unstructured":"Leone A, Colamaria A, Fochi NP, Sacco M, Landriscina M, Parbonetti G, et al. Recurrent glioblastoma treatment: state of the art and future perspectives in the precision medicine era. Biomedicines. 2022;10(8):1927. https:\/\/doi.org\/10.3390\/biomedicines10081927.","journal-title":"Biomedicines"},{"issue":"9","key":"4401_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/14737140.2020.1807949","volume":"20","author":"V Di Nunno","year":"2020","unstructured":"Di Nunno V, Franceschi E, Tosoni A, Di Battista M, Gatto L, Lamperini C, et al. Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. Expert Rev Anticancer Ther. 2020;20(9):785\u201395. https:\/\/doi.org\/10.1080\/14737140.2020.1807949.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"4401_CR4","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","volume":"18","author":"PD Delgado-L\u00f3pez","year":"2016","unstructured":"Delgado-L\u00f3pez PD, Corrales-Garc\u00eda EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18(11):1062\u201371. https:\/\/doi.org\/10.1007\/s12094-016-1497-x.","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"4401_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s12094-020-02340-8","volume":"22","author":"PD Delgado-L\u00f3pez","year":"2020","unstructured":"Delgado-L\u00f3pez PD, Saiz-L\u00f3pez P, Gargini R, Sola-Vendrell E, Tejada S. A comprehensive overview on the molecular biology of human glioma: what the clinician needs to know. Clin Transl Oncol. 2020;22(11):1909\u201322. https:\/\/doi.org\/10.1007\/s12094-020-02340-8.","journal-title":"Clin Transl Oncol"},{"key":"4401_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00286","volume":"10","author":"YH Zhao","year":"2019","unstructured":"Zhao YH, Wang ZF, Pan ZY, P\u00e9us D, Delgado-Fernandez J, Pallud J, et al. A meta-analysis of survival outcomes following reoperation in recurrent glioblastoma: time to consider the timing of reoperation. Front Neurol. 2019;10:286. https:\/\/doi.org\/10.3389\/fneur.2019.00286.","journal-title":"Front Neurol"},{"issue":"2","key":"4401_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/nop\/npy019","volume":"6","author":"M Shanker","year":"2019","unstructured":"Shanker M, Chua B, Bettington C, Foote MC, Pinkham MB. Re-irradiation for recurrent high-grade gliomas: a systematic review and analysis of treatment technique with respect to survival and risk of radionecrosis. Neurooncol Pract. 2019;6(2):144\u201355. https:\/\/doi.org\/10.1093\/nop\/npy019.","journal-title":"Neurooncol Pract"},{"issue":"20","key":"4401_CR8","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and Bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1707358.","journal-title":"N Engl J Med"},{"issue":"10","key":"4401_CR9","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.ejca.2015.03.025","volume":"51","author":"L Dirven","year":"2015","unstructured":"Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, et al. The impact of Bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer. 2015;51(10):1321\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.025.","journal-title":"Eur J Cancer"},{"issue":"4","key":"4401_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.6004\/jnccn.2011.0037","volume":"9","author":"ET Wong","year":"2011","unstructured":"Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw. 2011;9(4):403\u20137. https:\/\/doi.org\/10.6004\/jnccn.2011.0037.","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"4401_CR11","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192\u2013202. https:\/\/doi.org\/10.1016\/j.ejca.2012.04.011.","journal-title":"Eur J Cancer"},{"issue":"23","key":"4401_CR12","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance Temozolomide vs maintenance Temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306\u201316. https:\/\/doi.org\/10.1001\/jama.2017.18718.","journal-title":"JAMA"},{"issue":"4","key":"4401_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/nop\/npab026","volume":"8","author":"O Regev","year":"2021","unstructured":"Regev O, Merkin V, Blumenthal DT, Melamed I, Kaisman-Elbaz T. Tumor-treating fields for the treatment of glioblastoma: a systematic review and meta-analysis. Neuro-oncol Pract. 2021;8(4):426\u201340. https:\/\/doi.org\/10.1093\/nop\/npab026.","journal-title":"Neuro-oncol Pract"},{"issue":"3","key":"4401_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/neuonc\/noac216","volume":"25","author":"JAF Koekkoek","year":"2023","unstructured":"Koekkoek JAF, van der Meer PB, Pace A, Hertler C, Harrison R, Leeper HE, et al. Palliative care and end-of-life care in adults with malignant brain tumors. Neuro Oncol. 2023;25(3):447\u201356. https:\/\/doi.org\/10.1093\/neuonc\/noac216.","journal-title":"Neuro Oncol"},{"issue":"11","key":"4401_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s11910-023-01301-2","volume":"23","author":"JY Rhee","year":"2023","unstructured":"Rhee JY, Strander S, Podgurski A, Chiu D, Brizzi K, Forst DA. Palliative care in neuro-oncology: an update. Curr Neurol Neurosci Rep. 2023;23(11):645\u201356. https:\/\/doi.org\/10.1007\/s11910-023-01301-2.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"12","key":"4401_CR16","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.2011.37.3795","volume":"30","author":"M Maltoni","year":"2012","unstructured":"Maltoni M, Scarpi E, Rosati M, Derni S, Fabbri L, Martini F, et al. Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol. 2012;30(12):1378\u201383. https:\/\/doi.org\/10.1200\/JCO.2011.37.3795.","journal-title":"J Clin Oncol"},{"key":"4401_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2021-107523","author":"TR Velasco Sanz","year":"2021","unstructured":"Velasco Sanz TR, Pinto Pastor P, Moreno-Mil\u00e1n B, Mower Hanlon LF, Herreros B. Spanish regulation of euthanasia and physician-assisted suicide. J Med Ethics. 2021. https:\/\/doi.org\/10.1136\/medethics-2021-107523.","journal-title":"J Med Ethics"},{"key":"4401_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n147","volume":"372","author":"AG Rada","year":"2021","unstructured":"Rada AG. Spain will become the sixth country worldwide to allow euthanasia and assisted suicide. BMJ. 2021;372:n147. https:\/\/doi.org\/10.1136\/bmj.n147.","journal-title":"BMJ"},{"issue":"10","key":"4401_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"issue":"4","key":"4401_CR20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3171\/2012.9.JNS1277","volume":"118","author":"KL Chaichana","year":"2013","unstructured":"Chaichana KL, Zadnik P, Weingart JD, Olivi A, Gallia GL, Blakeley J, et al. Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg. 2013;118(4):812\u201320. https:\/\/doi.org\/10.3171\/2012.9.JNS1277.","journal-title":"J Neurosurg"},{"issue":"6","key":"4401_CR21","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3171\/2012.9.JNS12504","volume":"117","author":"O Bloch","year":"2012","unstructured":"Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg. 2012;117(6):1032\u20138. https:\/\/doi.org\/10.3171\/2012.9.JNS12504.","journal-title":"J Neurosurg"},{"issue":"4","key":"4401_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3171\/2013.12.JNS13184","volume":"120","author":"ME Oppenlander","year":"2014","unstructured":"Oppenlander ME, Wolf AB, Snyder LA, Bina R, Wilson JR, Coons SW, et al. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J Neurosurg. 2014;120(4):846\u201353. https:\/\/doi.org\/10.3171\/2013.12.JNS13184.","journal-title":"J Neurosurg"},{"issue":"1","key":"4401_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/neuonc\/nov145","volume":"18","author":"F Ringel","year":"2016","unstructured":"Ringel F, Pape H, Sabel M, Krex D, Bock HC, Misch M, et al. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol. 2016;18(1):96\u2013104. https:\/\/doi.org\/10.1093\/neuonc\/nov145.","journal-title":"Neuro Oncol"},{"issue":"2","key":"4401_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11060-014-1397-2","volume":"117","author":"J Quick","year":"2014","unstructured":"Quick J, Gessler F, D\u00fctzmann S, Hattingen E, Harter PN, Weise LM, et al. Benefit of tumor resection for recurrent glioblastoma. J Neurooncol. 2014;117(2):365\u201372. https:\/\/doi.org\/10.1007\/s11060-014-1397-2.","journal-title":"J Neurooncol"},{"issue":"24","key":"4401_CR25","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2010.30.0582","volume":"28","author":"JK Park","year":"2010","unstructured":"Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28(24):3838\u201343. https:\/\/doi.org\/10.1200\/JCO.2010.30.0582.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4401_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/neuonc\/nov326","volume":"18","author":"B Suchorska","year":"2016","unstructured":"Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol. 2016;18(4):549\u201356. https:\/\/doi.org\/10.1093\/neuonc\/nov326.","journal-title":"Neuro Oncol"},{"issue":"1","key":"4401_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/2011.2.jns10998","volume":"115","author":"N Sanai","year":"2011","unstructured":"Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3\u20138. https:\/\/doi.org\/10.3171\/2011.2.jns10998.","journal-title":"J Neurosurg"},{"issue":"5","key":"4401_CR28","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3171\/2014.7.JNS132449","volume":"121","author":"MM Grabowski","year":"2014","unstructured":"Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014;121(5):1115\u201323. https:\/\/doi.org\/10.3171\/2014.7.JNS132449.","journal-title":"J Neurosurg"},{"issue":"3","key":"4401_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170\u201386. https:\/\/doi.org\/10.1038\/s41571-020-00447-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4401_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1227\/NEU.0b013e318223f5a7","volume":"70","author":"MA Vogelbaum","year":"2012","unstructured":"Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, et al. Application of novel response\/progression measures for surgically delivered therapies for gliomas: response assessment in neuro-oncology (RANO) working group. Neurosurgery. 2012;70(1):234\u201343. https:\/\/doi.org\/10.1227\/NEU.0b013e318223f5a7. (discussion 243-4.).","journal-title":"Neurosurgery"},{"issue":"5","key":"4401_CR31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","volume":"7","author":"W Stummer","year":"2006","unstructured":"Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392\u2013401. https:\/\/doi.org\/10.1016\/S1470-2045(06)70665-9.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4401_CR32","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1227\/01.NEU.0000360128.03597.C7","volume":"65","author":"A Nabavi","year":"2009","unstructured":"Nabavi A, Thurm H, Zountsas B, Pietsch T, Lanfermann H, Pichlmeier U, et al. Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase II study. Neurosurgery. 2009;65(6):1070\u20136. https:\/\/doi.org\/10.1227\/01.NEU.0000360128.03597.C7. (discussion 1076-7.).","journal-title":"Neurosurgery"},{"issue":"2","key":"4401_CR33","doi-asserted-by":"publisher","DOI":"10.3171\/2013.12.FOCUS13464","volume":"36","author":"S Marbacher","year":"2014","unstructured":"Marbacher S, Klinger E, Schwyzer L, Fischer I, Nevzati E, Diepers M, et al. Use of fluorescence to guide resection or biopsy of primary brain tumors and brain metastases. Neurosurg Focus. 2014;36(2):E10. https:\/\/doi.org\/10.3171\/2013.12.FOCUS13464.","journal-title":"Neurosurg Focus"},{"issue":"20","key":"4401_CR34","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1200\/JCO.2011.38.4818","volume":"30","author":"PC De Witt Hamer","year":"2012","unstructured":"De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012;30(20):2559\u201365. https:\/\/doi.org\/10.1200\/JCO.2011.38.4818.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4401_CR35","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1227\/01.NEU.0000369514.74284.78","volume":"66","author":"A De Benedictis","year":"2010","unstructured":"De Benedictis A, Moritz-Gasser S, Duffau H. Awake mapping optimizes the extent of resection for low-grade gliomas in eloquent areas. Neurosurgery. 2010;66(6):1074\u201384. https:\/\/doi.org\/10.1227\/01.NEU.0000369514.74284.78.","journal-title":"Neurosurgery"},{"issue":"3","key":"4401_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40477-014-0111-8","volume":"17","author":"F Prada","year":"2014","unstructured":"Prada F, Del Bene M, Mattei L, Casali C, Filippini A, Legnani F, et al. Fusion imaging for intra-operative ultrasound-based navigation in neurosurgery. J Ultrasound. 2014;17(3):243\u201351. https:\/\/doi.org\/10.1007\/s40477-014-0111-8.","journal-title":"J Ultrasound"},{"issue":"4","key":"4401_CR37","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/00006123-200204000-00022","volume":"50","author":"G Unsgaard","year":"2002","unstructured":"Unsgaard G, Ommedal S, Muller T, Gronningsaeter A, Nagelhus Hernes TA. Neuronavigation by intraoperative three-dimensional ultrasound: initial experience during brain tumor resection. Neurosurgery. 2002;50(4):804\u201312. https:\/\/doi.org\/10.1097\/00006123-200204000-00022.","journal-title":"Neurosurgery"},{"issue":"1","key":"4401_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3171\/2008.4.17536","volume":"110","author":"MJ McGirt","year":"2009","unstructured":"McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156\u201362. https:\/\/doi.org\/10.3171\/2008.4.17536.","journal-title":"J Neurosurg"},{"issue":"4","key":"4401_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/archneurol.2011.2910","volume":"69","author":"F Sahm","year":"2012","unstructured":"Sahm F, Capper D, Jeibmann A, Habel A, Paulus W, Troost D. Addressing diffuse glioma as a systemic brain disease with single-cell analysis. Arch Neurol. 2012;69(4):523\u20136. https:\/\/doi.org\/10.1001\/archneurol.2011.2910.","journal-title":"Arch Neurol"},{"key":"4401_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.11.024","volume":"181","author":"G Minniti","year":"2023","unstructured":"Minniti G, Tini P, Giraffa M, Capone L, Raza G, Russo I, et al. Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis. Radiother Oncol. 2023;181:109435. https:\/\/doi.org\/10.1016\/j.radonc.2022.11.024.","journal-title":"Radiother Oncol"},{"issue":"8","key":"4401_CR41","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2008.19.4969","volume":"27","author":"AA Brandes","year":"2009","unstructured":"Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amist\u00e0 P, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol. 2009;27(8):1275\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.19.4969.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4401_CR42","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/nop\/npae040","volume":"11","author":"DBP Eekers","year":"2024","unstructured":"Eekers DBP, Zegers CML, Ahmed KA, Amelio D, Gupta T, Harrabi SB, et al. Controversies in neuro-oncology: focal proton versus photon radiation therapy for adult brain tumors. Neuro-oncol Pract. 2024;11(4):369\u201382. https:\/\/doi.org\/10.1093\/nop\/npae040.","journal-title":"Neuro-oncol Pract"},{"issue":"11","key":"4401_CR43","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.21873\/anticanres.12954","volume":"38","author":"C Scaringi","year":"2018","unstructured":"Scaringi C, Agolli L, Minniti G. Technical advances in radiation therapy for brain tumors. Anticancer Res. 2018;38(11):6041\u20135. https:\/\/doi.org\/10.21873\/anticanres.12954.","journal-title":"Anticancer Res"},{"issue":"9","key":"4401_CR44","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68820","volume":"16","author":"AN Reinders","year":"2024","unstructured":"Reinders AN, Koshy M, Korpics M. The patterns of failure and prognostic impact of tumor location in patients undergoing reirradiation for glioblastoma. Cureus. 2024;16(9):e68820. https:\/\/doi.org\/10.7759\/cureus.68820.","journal-title":"Cureus"},{"issue":"2","key":"4401_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/cancers4020379","volume":"4","author":"P Sminia","year":"2012","unstructured":"Sminia P, Mayer R. External beam radiotherapy of recurrent glioma: radiation tolerance of the human brain. Cancers (Basel). 2012;4(2):379\u201399. https:\/\/doi.org\/10.3390\/cancers4020379.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4401_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01767-9","volume":"16","author":"G Minniti","year":"2021","unstructured":"Minniti G, Niyazi M, Alongi F, Navarria P, Belka C. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol. 2021;16(1):36. https:\/\/doi.org\/10.1186\/s13014-021-01767-9.","journal-title":"Radiat Oncol"},{"issue":"10","key":"4401_CR47","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","volume":"23","author":"N Andratschke","year":"2022","unstructured":"Andratschke N, Willmann J, Appelt AL, Alyamani N, Balermpas P, Baumert BG, et al. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol. 2022;23(10):e469\u201378. https:\/\/doi.org\/10.1016\/S1470-2045(22)00447-8.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4401_CR48","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/CCO.0000000000001192","volume":"37","author":"T Kazda","year":"2025","unstructured":"Kazda T, Hnidakova L, Minniti G. Reirradiation in recurrent glioblastoma. Curr Opin Oncol. 2025;37(6):580\u20138. https:\/\/doi.org\/10.1097\/CCO.0000000000001192.","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"4401_CR49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11060-023-04407-2","volume":"164","author":"R De Pietro","year":"2023","unstructured":"De Pietro R, Zaccaro L, Marampon F, Tini P, De Felice F, Minniti G. The evolving role of reirradiation in the management of recurrent brain tumors. J Neurooncol. 2023;164(2):271\u201386. https:\/\/doi.org\/10.1007\/s11060-023-04407-2.","journal-title":"J Neurooncol"},{"issue":"24","key":"4401_CR50","doi-asserted-by":"publisher","first-page":"6304","DOI":"10.1158\/1078-0432.CCR-14-0951-T","volume":"20","author":"W Wick","year":"2014","unstructured":"Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, et al. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res. 2014;20(24):6304\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0951-T.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4401_CR51","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.22.00164","volume":"41","author":"CI Tsien","year":"2023","unstructured":"Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, et al. NRG Oncology\/RTOG1205: a randomized phase II trial of concurrent Bevacizumab and reirradiation versus Bevacizumab alone as treatment for recurrent glioblastoma. J Clin Oncol. 2023;41(6):1285\u201395. https:\/\/doi.org\/10.1200\/JCO.22.00164.","journal-title":"J Clin Oncol"},{"issue":"34","key":"4401_CR52","doi-asserted-by":"publisher","first-page":"8863","DOI":"10.1200\/JCO.2005.03.4157","volume":"23","author":"SE Combs","year":"2005","unstructured":"Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23(34):8863\u20139. https:\/\/doi.org\/10.1200\/JCO.2005.03.4157.","journal-title":"J Clin Oncol"},{"issue":"18","key":"4401_CR53","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","volume":"28","author":"SE Fogh","year":"2010","unstructured":"Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010;28(18):3048\u201353. https:\/\/doi.org\/10.1200\/JCO.2009.25.6941.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4401_CR54","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s11060-018-2989-z","volume":"140","author":"JD Palmer","year":"2018","unstructured":"Palmer JD, Bhamidipati D, Song A, Eldredge-Hindy HB, Siglin J, Dan TD, et al. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? J Neurooncol. 2018;140(3):623\u20138. https:\/\/doi.org\/10.1007\/s11060-018-2989-z.","journal-title":"J Neurooncol"},{"issue":"7","key":"4401_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216111","volume":"14","author":"DF Fleischmann","year":"2019","unstructured":"Fleischmann DF, Unterrainer M, Corradini S, Rottler M, F\u00f6rster S, la Foug\u00e8re C, et al. Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation. PLoS ONE. 2019;14(7):e0216111. https:\/\/doi.org\/10.1371\/journal.pone.0216111.","journal-title":"PLoS ONE"},{"issue":"2","key":"4401_CR56","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ijrobp.2005.01.056","volume":"63","author":"AL Grosu","year":"2005","unstructured":"Grosu AL, Weber WA, Franz M, St\u00e4rk S, Piert M, Thamm R, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)\/CT\/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(2):511\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.01.056.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4401_CR57","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s11060-010-0446-8","volume":"103","author":"G Minniti","year":"2011","unstructured":"Minniti G, Armosini V, Salvati M, Lanzetta G, Caporello P, Mei M, et al. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol. 2011;103(3):683\u201391. https:\/\/doi.org\/10.1007\/s11060-010-0446-8.","journal-title":"J Neurooncol"},{"issue":"2","key":"4401_CR58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11060-012-0999-9","volume":"111","author":"G Minniti","year":"2013","unstructured":"Minniti G, Scaringi C, De Sanctis V, Lanzetta G, Falco T, Di Stefano D, et al. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas. J Neurooncol. 2013;111(2):187\u201394. https:\/\/doi.org\/10.1007\/s11060-012-0999-9.","journal-title":"J Neurooncol"},{"key":"4401_CR59","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2147\/OTT.S60358","volume":"7","author":"JN Greenspoon","year":"2014","unstructured":"Greenspoon JN, Sharieff W, Hirte H, Overholt A, Devillers R, Gunnarsson T, et al. Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study. Onco Targets Ther. 2014;7:485\u201390. https:\/\/doi.org\/10.2147\/OTT.S60358.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"4401_CR60","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ijrobp.2010.12.074","volume":"82","author":"KC Cuneo","year":"2012","unstructured":"Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, et al. Safety and efficacy of stereotactic radiosurgery and adjuvant Bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012;82(5):2018\u201324. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.12.074.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4401_CR61","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11060-014-1394-5","volume":"117","author":"M Flieger","year":"2014","unstructured":"Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Foug\u00e8re C, et al. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol. 2014;117(2):337\u201345. https:\/\/doi.org\/10.1007\/s11060-014-1394-5.","journal-title":"J Neurooncol"},{"issue":"3","key":"4401_CR62","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11060-016-2267-x","volume":"130","author":"O Schnell","year":"2016","unstructured":"Schnell O, Thorsteinsdottir J, Fleischmann DF, Lenski M, Abenhardt W, Giese A, et al. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. J Neurooncol. 2016;130(3):591\u20139. https:\/\/doi.org\/10.1007\/s11060-016-2267-x.","journal-title":"J Neurooncol"},{"key":"4401_CR63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.radonc.2019.06.009","volume":"138","author":"DF Fleischmann","year":"2019","unstructured":"Fleischmann DF, Jenn J, Corradini S, Ruf V, Herms J, Forbrig R, et al. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma. Radiother Oncol. 2019;138:99\u2013105. https:\/\/doi.org\/10.1016\/j.radonc.2019.06.009.","journal-title":"Radiother Oncol"},{"issue":"1","key":"4401_CR64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11060-013-1044-3","volume":"112","author":"T Hundsberger","year":"2013","unstructured":"Hundsberger T, Br\u00fcgge D, Putora PM, Weder P, Weber J, Plasswilm L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol. 2013;112(1):133\u20139. https:\/\/doi.org\/10.1007\/s11060-013-1044-3.","journal-title":"J Neurooncol"},{"issue":"5","key":"4401_CR65","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/cam4.1425","volume":"7","author":"SE Combs","year":"2018","unstructured":"Combs SE, Niyazi M, Adeberg S, Bougatf N, Kaul D, Fleischmann DF, et al. Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). Cancer Med. 2018;7(5):1742\u20139. https:\/\/doi.org\/10.1002\/cam4.1425.","journal-title":"Cancer Med"},{"issue":"1","key":"4401_CR66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11060-018-03059-x","volume":"142","author":"P Navarria","year":"2019","unstructured":"Navarria P, Minniti G, Clerici E, Tomatis S, Pinzi V, Ciammella P, et al. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. a multicenter study of the radiation oncology italian association (AIRO). J Neurooncol. 2019;142(1):59\u201367. https:\/\/doi.org\/10.1007\/s11060-018-03059-x.","journal-title":"J Neurooncol"},{"issue":"44","key":"4401_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100697","volume":"30","author":"SM Christ","year":"2023","unstructured":"Christ SM, Youssef G, Tanguturi SK, Cagney D, Shi D, McFaline-Figueroa JR, et al. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence. Clin Transl Radiat Oncol. 2023;30(44):100697. https:\/\/doi.org\/10.1016\/j.ctro.2023.100697.","journal-title":"Clin Transl Radiat Oncol"},{"key":"4401_CR68","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.wneu.2017.02.061","volume":"102","author":"L St\u00f6ckelmaier","year":"2017","unstructured":"St\u00f6ckelmaier L, Renovanz M, K\u00f6nig J, Nickel K, Hickmann AK, Mayer-Steinacker R, et al. Therapy for recurrent high-grade gliomas: results of a prospective multicenter study on health-related quality of life. World Neurosurg. 2017;102:383\u201399. https:\/\/doi.org\/10.1016\/j.wneu.2017.02.061.","journal-title":"World Neurosurg"},{"issue":"3","key":"4401_CR69","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11060-019-03320-x","volume":"145","author":"W Wick","year":"2019","unstructured":"Wick W, Krendyukov A, Junge K, H\u00f6ger T, Fricke H. Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients. J Neurooncol. 2019;145(3):531\u201340. https:\/\/doi.org\/10.1007\/s11060-019-03320-x.","journal-title":"J Neurooncol"},{"issue":"2","key":"4401_CR70","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11060-020-03526-4","volume":"148","author":"D Bergman","year":"2020","unstructured":"Bergman D, Modh A, Schultz L, Snyder J, Mikkelsen T, Shah M, et al. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. J Neurooncol. 2020;148(2):353\u201361. https:\/\/doi.org\/10.1007\/s11060-020-03526-4.","journal-title":"J Neurooncol"},{"issue":"7650","key":"4401_CR71","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"1","key":"4401_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-08213-7","volume":"25","author":"M Preusser","year":"2024","unstructured":"Preusser M, Kazda T, Le Rhun E, Sahm F, Smits M, Gempt J, et al. Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study. Trials. 2024;25(1):366. https:\/\/doi.org\/10.1186\/s13063-024-08213-7.","journal-title":"Trials"},{"issue":"4","key":"4401_CR73","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.21.02036","volume":"40","author":"NA Mohile","year":"2022","unstructured":"Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022;40(4):403\u201326. https:\/\/doi.org\/10.1200\/JCO.21.02036.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4401_CR74","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1007\/s12094-023-03245-y","volume":"25","author":"PP Segura","year":"2023","unstructured":"Segura PP, Quintela NV, Garc\u00eda MM, Del Barco Berr\u00f3n S, Sarri\u00f3 RG, et al. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022). Clin Transl Oncol. 2023;25(9):2634\u201346. https:\/\/doi.org\/10.1007\/s12094-023-03245-y.","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"4401_CR75","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bi\u00e8che I, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35(7):588\u2013606. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005.","journal-title":"Ann Oncol"},{"issue":"5","key":"4401_CR76","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/neuonc\/noad008","volume":"25","author":"D Capper","year":"2023","unstructured":"Capper D, Reifenberger G, French PJ, Schweizer L, Weller M, Touat M, et al. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro Oncol. 2023;25(5):813\u201326. https:\/\/doi.org\/10.1093\/neuonc\/noad008.","journal-title":"Neuro Oncol"},{"key":"4401_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102029","volume":"87","author":"M Weller","year":"2020","unstructured":"Weller M, Le Rhun E. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev. 2020;87:102029. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102029.","journal-title":"Cancer Treat Rev"},{"key":"4401_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103540","volume":"169","author":"FGT Fazzari","year":"2022","unstructured":"Fazzari FGT, Rose F, Pauls M, Guay E, Ibrahim MFK, Basulaiman B, et al. The current landscape of systemic therapy for recurrent glioblastoma: a systematic review of randomized-controlled trials. Crit Rev Oncol Hematol. 2022;169:103540. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103540.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"4401_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae338","volume":"30","author":"F Schettini","year":"2025","unstructured":"Schettini F, Pineda E, Rocca A, Buch\u00e9 V, Donofrio CA, Mazariegos M, et al. Identifying the best treatment choice for relapsing\/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses. Oncologist. 2025;30(7):oyae338. https:\/\/doi.org\/10.1093\/oncolo\/oyae338.","journal-title":"Oncologist"},{"issue":"5","key":"4401_CR80","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s00415-009-5006-9","volume":"256","author":"A Wick","year":"2009","unstructured":"Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, et al. Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol. 2009;256(5):734\u201341. https:\/\/doi.org\/10.1007\/s00415-009-5006-9.","journal-title":"J Neurol"},{"issue":"9","key":"4401_CR81","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-14-2737","volume":"21","author":"M Weller","year":"2015","unstructured":"Weller M, Tabatabai G, K\u00e4stner B, Felsberg J, Steinbach JP, Wick A, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res. 2015;21(9):2057\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2737.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4401_CR82","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.2217\/fon-2017-0681","volume":"14","author":"E Franceschi","year":"2018","unstructured":"Franceschi E, Lamberti G, Visani M, Paccapelo A, Mura A, Tallini G, et al. Temozolomide rechallenge in recurrent glioblastoma: when is it useful? Future Oncol. 2018;14(11):1063\u20139. https:\/\/doi.org\/10.2217\/fon-2017-0681.","journal-title":"Future Oncol"},{"issue":"32","key":"4401_CR83","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1200\/JCO.22.02772","volume":"41","author":"HS Friedman","year":"2023","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with Irinotecan in recurrent glioblastoma. J Clin Oncol. 2023;41(32):4945\u201352. https:\/\/doi.org\/10.1200\/JCO.22.02772.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4401_CR84","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","volume":"13","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of Bevacizumab and Irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2309.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4401_CR85","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","volume":"20","author":"G Lombardi","year":"2019","unstructured":"Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rud\u00e0 R, Faedi M, et al. Regorafenib compared with Lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019;20(1):110\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(18)30675-2.","journal-title":"Lancet Oncol"},{"issue":"Supplement_5","key":"4401_CR86","doi-asserted-by":"publisher","first-page":"v26","DOI":"10.1093\/neuonc\/noae144.079","volume":"26","author":"A Lassman","year":"2024","unstructured":"Lassman A, Alexander B, Berry D, Buxton M, Cavenee W, Colman H, et al. OS09.7.A GBM AGILE platform trial for newly diagnosed and recurrent GBM: results of first experimental arm, regorafenib. Neuro-oncol. 2024;26(Supplement_5):v26\u20137.","journal-title":"Neuro-oncol"},{"issue":"26","key":"4401_CR87","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","volume":"31","author":"TT Batchelor","year":"2013","unstructured":"Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212\u20138. https:\/\/doi.org\/10.1200\/JCO.2012.47.2464.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4401_CR88","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003\u201310. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1024.","journal-title":"JAMA Oncol"},{"issue":"23","key":"4401_CR89","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535\u201343. https:\/\/doi.org\/10.1001\/jama.2015.16669.","journal-title":"JAMA"},{"issue":"1","key":"4401_CR90","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","volume":"23","author":"PY Wen","year":"2022","unstructured":"Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, et al. Dabrafenib plus Trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022;23(1):53\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(21)00578-7.","journal-title":"Lancet Oncol"},{"issue":"10","key":"4401_CR91","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/neuonc\/noac087","volume":"24","author":"AV Desai","year":"2022","unstructured":"Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, et al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022;24(10):1776\u201389. https:\/\/doi.org\/10.1093\/neuonc\/noac087.","journal-title":"Neuro Oncol"},{"issue":"10","key":"4401_CR92","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with Pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4401_CR93","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/cas.16370","volume":"116","author":"A Nishiyama","year":"2025","unstructured":"Nishiyama A, Sato S, Sakaguchi H, Kotani H, Yamashita K, Ohtsubo K, et al. Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: a case study and implications for precision oncology. Cancer Sci. 2025;116(1):271\u20136. https:\/\/doi.org\/10.1111\/cas.16370.","journal-title":"Cancer Sci"},{"issue":"5","key":"4401_CR94","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/neuonc\/noz222","volume":"22","author":"M Van Den Bent","year":"2020","unstructured":"Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, et al. INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with Temozolomide vs Temozolomide or Lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2020;22(5):684\u201393. https:\/\/doi.org\/10.1093\/neuonc\/noz222.","journal-title":"Neuro Oncol"},{"issue":"14","key":"4401_CR95","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419\u201327. https:\/\/doi.org\/10.1200\/JCO.2017.75.8219.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4401_CR96","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a Phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023;9(1):112\u201321. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5370.","journal-title":"JAMA Oncol"},{"issue":"399","key":"4401_CR97","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O'Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984.","journal-title":"Sci Transl Med"},{"issue":"26","key":"4401_CR98","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of Glioblastoma after chimeric antigen receptor T-Cell therapy. N Engl J Med. 2016;375(26):2561\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1610497.","journal-title":"N Engl J Med"},{"issue":"4","key":"4401_CR99","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024;30(4):1001\u201312. https:\/\/doi.org\/10.1038\/s41591-024-02875-1.","journal-title":"Nat Med"},{"issue":"24","key":"4401_CR100","doi-asserted-by":"publisher","first-page":"10152","DOI":"10.1073\/pnas.0702916104","volume":"104","author":"ED Kirson","year":"2007","unstructured":"Kirson ED, Dbal\u00fd V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007;104(24):10152\u20137. https:\/\/doi.org\/10.1073\/pnas.0702916104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"4401_CR101","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae227","volume":"30","author":"S Khagi","year":"2025","unstructured":"Khagi S, Kotecha R, Gatson NTN, Jeyapalan S, Abdullah HI, Avgeropoulos NG, et al. Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma. Oncologist. 2025;30(2):oyae227. https:\/\/doi.org\/10.1093\/oncolo\/oyae227.","journal-title":"Oncologist"},{"issue":"8","key":"4401_CR102","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149258","volume":"132","author":"D Chen","year":"2022","unstructured":"Chen D, Le SB, Hutchinson TE, Calinescu AA, Sebastian M, Jin D, et al. Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in Glioblastoma. J Clin Invest. 2022;132(8):e149258. https:\/\/doi.org\/10.1172\/JCI149258.","journal-title":"J Clin Invest"},{"key":"4401_CR103","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lungcan.2021.08.011","volume":"160","author":"H Mumblat","year":"2021","unstructured":"Mumblat H, Martinez-Conde A, Braten O, Munster M, Dor-On E, Schneiderman RS, et al. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models. Lung Cancer. 2021;160:99\u2013110. https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.011.","journal-title":"Lung Cancer"},{"issue":"10","key":"4401_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103016","volume":"12","author":"T Voloshin","year":"2020","unstructured":"Voloshin T, Schneiderman RS, Volodin A, Shamir RR, Kaynan N, Zeevi E, et al. Tumor Treating Fields (TTFields) hinder cancer cell motility through regulation of microtubule and acting dynamics. Cancers (Basel). 2020;12(10):3016. https:\/\/doi.org\/10.3390\/cancers12103016.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"4401_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101348","volume":"12","author":"E Salvador","year":"2022","unstructured":"Salvador E, Kessler AF, Domr\u00f6se D, H\u00f6rmann J, Schaeffer C, Giniunaite A, et al. Tumor Treating Fields (TTFields) reversibly permeabilize the Blood-Brain Barrier in vitro and in vivo. Biomolecules. 2022;12(10):1348. https:\/\/doi.org\/10.3390\/biom12101348.","journal-title":"Biomolecules"},{"issue":"Suppl 6","key":"4401_CR106","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1053\/j.seminoncol.2014.09.010","volume":"41","author":"MM Mrugala","year":"2014","unstructured":"Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, et al. Clinical practice experience with NovoTTF-100A\u2122 system for glioblastoma: the Patient Registry Dataset (PRiDe). Semin Oncol. 2014;41(Suppl 6):S4\u201313. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.09.010.","journal-title":"Semin Oncol"},{"issue":"1","key":"4401_CR107","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-022-00555-5","volume":"13","author":"JJ Zhu","year":"2022","unstructured":"Zhu JJ, Goldlust SA, Kleinberg LR, Honnorat J, Oberheim Bush NA, Ram Z. Tumor Treating Fields (TTFields) therapy vs physicians\u2019 choice standard-of-care treatment in patients with recurrent Glioblastoma: a post-approval registry study (EF-19). Discov Oncol. 2022;13(1):105. https:\/\/doi.org\/10.1007\/s12672-022-00555-5.","journal-title":"Discov Oncol"},{"issue":"1","key":"4401_CR108","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11060-021-03755-1","volume":"153","author":"A Dono","year":"2021","unstructured":"Dono A, Mitra S, Shah M, Takayasu T, Zhu JJ, Tandon N, et al. PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma. J Neurooncol. 2021;153(1):153\u201360. https:\/\/doi.org\/10.1007\/s11060-021-03755-1.","journal-title":"J Neurooncol"},{"key":"4401_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01045","volume":"10","author":"ME Lacouture","year":"2020","unstructured":"Lacouture ME, Anadkat MJ, Ballo MT, Iwamoto F, Jeyapalan SA, La Rocca RV, et al. Prevention and management of dermatologic adverse events associated with Tumor Treating Fields in patients with Glioblastoma. Front Oncol. 2020;10:1045. https:\/\/doi.org\/10.3389\/fonc.2020.01045.","journal-title":"Front Oncol"},{"issue":"2","key":"4401_CR110","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11060-018-03057-z","volume":"141","author":"SA Toms","year":"2019","unstructured":"Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467\u201373. https:\/\/doi.org\/10.1007\/s11060-018-03057-z.","journal-title":"J Neurooncol"},{"issue":"4","key":"4401_CR111","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","volume":"4","author":"MJB Taphoorn","year":"2018","unstructured":"Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, et al. Influence of treatment with Tumor-Treating Fields on health-related quality of life of patients with newly diagnosed Glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495\u2013504. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5082.","journal-title":"JAMA Oncol"},{"issue":"3","key":"4401_CR112","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2217\/cns-2016-0049","volume":"6","author":"S Kesari","year":"2017","unstructured":"Kesari S, Ram Z, EF-14 Trial Investigators. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. CNS Oncol. 2017;6(3):185\u201393. https:\/\/doi.org\/10.2217\/cns-2016-0049.","journal-title":"CNS Oncol"},{"key":"4401_CR113","unstructured":"Ministerio de Sanidad. Resoluci\u00f3n de 14 de agosto de 2025, de la Direcci\u00f3n General de Cartera Com\u00fan de Servicios del Sistema Nacional de Salud y Farmacia, por la que se determina el sometimiento de la terapia de campos el\u00e9ctricos alternos para el tratamiento de tumores (Tumor Treating Fields, TTFields) en personas con glioblastoma de nuevo diagn\u00f3stico a estudio de monitorizaci\u00f3n y se establecen sus requisitos espec\u00edficos. Madrid: Ministerio de Sanidad; 2025. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/prestacionesSanitarias\/CarteraDeServicios\/ContenidoCS\/docs\/Resolucion_EM_TTFields.pdf. Accessed: December 13th, 2025."},{"issue":"6","key":"4401_CR114","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1212\/CON.0000000000000940","volume":"26","author":"DA Forst","year":"2020","unstructured":"Forst DA. Palliative and supportive care in Neuro-oncology. Continuum (Minneap Minn). 2020;26(6):1673\u201385. https:\/\/doi.org\/10.1212\/CON.0000000000000940.","journal-title":"Continuum (Minneap Minn)"},{"issue":"12","key":"4401_CR115","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/10499091241308883","volume":"42","author":"P Padhi","year":"2025","unstructured":"Padhi P, Gupta N, Bharati SJ, Garg R, Mishra S, Bhatnagar S, et al. Assessment of symptom burden and quality of life in patients with primary brain tumours attending palliative care in a tertiary cancer care centre. Am J Hosp Palliat Care. 2025;42(12):1284\u20139. https:\/\/doi.org\/10.1177\/10499091241308883.","journal-title":"Am J Hosp Palliat Care"},{"key":"4401_CR116","unstructured":"Palliative care. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/palliative-care. Accessed: 8th Dec 2025."},{"issue":"2","key":"4401_CR117","doi-asserted-by":"publisher","first-page":"142","DOI":"10.47102\/annals-acadmedsg.V37N2p142","volume":"37","author":"SA Murray","year":"2008","unstructured":"Murray SA, Kok JY. Internationally, it is time to bridge the gap between primary and secondary healthcare services for the dying. Ann Acad Med Singap. 2008;37(2):142\u20134.","journal-title":"Ann Acad Med Singap"},{"issue":"710","key":"4401_CR118","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3399\/bjgp21X716921","volume":"71","author":"S Murray","year":"2021","unstructured":"Murray S, Ambl\u00e0s J. Palliative care is increasing, but curative care is growing even faster in the last months of life. Br J Gen Pract. 2021;71(710):410\u20131. https:\/\/doi.org\/10.3399\/bjgp21X716921.","journal-title":"Br J Gen Pract"},{"key":"4401_CR119","unstructured":"Estrategia en cuidados paliativos del Sistema Nacional de Salud: actualizaci\u00f3n 2010\u20112014. Madrid: Ministerio de Sanidad, Pol\u00edtica Social e Igualdad; 2011. Available at: https:\/\/www.sanidad.gob.es\/areas\/calidadAsistencial\/estrategias\/cuidadosPaliativos\/docs\/cuidadospaliativos.pdf. Accessed: 8th Dec 2025"},{"key":"4401_CR120","unstructured":"Plan integral de cuidados paliativos de la Comunidad de Madrid 2017\u20132020. Madrid: Direcci\u00f3n General de Coordinaci\u00f3n de la Asistencia Sanitaria, Servicio Madrile\u00f1o de Salud; 2019. Available at: https:\/\/www.madrid.org\/bvirtual\/BVCM020297.pdf. Accessed: 8th Dec 2025."},{"key":"4401_CR121","unstructured":"Protocolos de tratamiento en cuidados paliativos. Available at: https:\/\/www.secpal.org\/wp-content\/uploads\/2024\/05\/protocolos-de-tratamiento-en-cuidados-paliativos-2023.pdf. Accessed: 8th Dec 2025"},{"key":"4401_CR122","unstructured":"Gu\u00eda pr\u00e1ctica para el manejo de la via subcut\u00e1nea. Servicio Aragon\u00e9s de Salud 2020. Available at: https:\/\/portal.guiasalud.es\/wp-content\/uploads\/2021\/04\/gpc_606_via_subcutanea_compl_rev.pdf. Accessed: 8th Dec 2025."},{"key":"4401_CR123","unstructured":"Enfermer\u00eda en Cuidados paliativos y al final de la vida. Available at: https:\/\/www.berri.es\/pdf\/ENFERMERIA%20EN%20CUIDADOS%20PALIATIVOS%20Y%20AL%20FINAL%20DE%20LA%20VIDA\/9788491136682. Accessed: 8th Dec 2025."},{"key":"4401_CR124","unstructured":"Gu\u00eda de sedaci\u00f3n paliativa. Organizaci\u00f3n m\u00e9dica colegial (OMC). Sociedad Espa\u00f1ola de Cuidados paliativos (SECPAL). Available at: https:\/\/www.cgcom.es\/sites\/main\/files\/mig\/guia_sedaccion_paliativa.pdf. Accessed: 8th Dec 2025."},{"issue":"5","key":"4401_CR125","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/nop\/npaf050","volume":"12","author":"L Fritz","year":"2025","unstructured":"Fritz L, Zaloumis E, Zwinkels H, Reijneveld JC, Vos MJ, Pasman HRW, et al. End-of-life care in patients with glioblastoma after early advance care planning. Neuro-oncol Pract. 2025;12(5):821\u20139. https:\/\/doi.org\/10.1093\/nop\/npaf050.","journal-title":"Neuro-oncol Pract"},{"issue":"6","key":"4401_CR126","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1212\/CON.0000000000001353","volume":"29","author":"A Sharma","year":"2023","unstructured":"Sharma A. Palliative care and care partner support in neuro-oncology. Continuum (Minneap). 2023;29(6):1872\u201395. https:\/\/doi.org\/10.1212\/CON.0000000000001353.","journal-title":"Continuum (Minneap)"},{"issue":"4","key":"4401_CR127","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3892\/mi.2025.245","volume":"5","author":"AM Al-Ghaithi","year":"2025","unstructured":"Al-Ghaithi AM, Al-Barkhati S, Al Abri AM, Al Husaini D, Al-Hajri A, Al-Saadi T. Palliative care in patients with glioblastoma: a systematic review. Med Int (Lond). 2025;5(4):46. https:\/\/doi.org\/10.3892\/mi.2025.245.","journal-title":"Med Int (Lond)"},{"issue":"01","key":"4401_CR128","doi-asserted-by":"publisher","first-page":"82","DOI":"10.32440\/ar.2025.142.01.org01","volume":"142","author":"M Herrera Abi\u00e1n","year":"2025","unstructured":"Herrera Abi\u00e1n M, Su\u00e1rez Rueda C, B\u00e1rcena Goitiandia L, Ant\u00f3n Rodr\u00edguez C, Jim\u00e9nez Rodr\u00edguez \u00c1. Muerte en el hospital: evaluaci\u00f3n econ\u00f3mica y calidad percibida cuando interviene un equipo de Cuidados Paliativos. An R Acad Nac Med. 2025;142(01):82\u201391. https:\/\/doi.org\/10.32440\/ar.2025.142.01.org01.","journal-title":"An R Acad Nac Med"},{"issue":"2","key":"4401_CR129","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2260400","volume":"55","author":"M Herrera-Abi\u00e1n","year":"2023","unstructured":"Herrera-Abi\u00e1n M, Casta\u00f1eda-Vozmediano R, Ant\u00f3n-Rodr\u00edguez C, Palacios-Ce\u00f1a D, Gonz\u00e1lez-Morales LM, Pfang B, et al. The caregiver\u2019s perspective on end-of-life inpatient palliative care: a qualitative study. Ann Med. 2023;55(2):2260400. https:\/\/doi.org\/10.1080\/07853890.2023.2260400.","journal-title":"Ann Med"},{"issue":"5","key":"4401_CR130","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jpainsymman.2022.06.016","volume":"64","author":"MH Abian","year":"2022","unstructured":"Abian MH, Ant\u00f3n Rodr\u00edguez C, Noguera A. End of life cost savings in the palliative care unit compared to other services. J Pain Symptom Manage. 2022;64(5):495\u2013503. https:\/\/doi.org\/10.1016\/j.jpainsymman.2022.06.016.","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"4401_CR131","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1227\/neu.0000000000002428","volume":"93","author":"JT Dullea","year":"2023","unstructured":"Dullea JT, Vasan V, Devarajan A, Ali M, Nichols N, Chaluts D, et al. Utilization of palliative care services among patients with malignant brain tumors: an analysis of the National Inpatient Sample (2016-2019). Neurosurgery. 2023;93(2):419\u201326. https:\/\/doi.org\/10.1227\/neu.0000000000002428.","journal-title":"Neurosurgery"},{"issue":"9","key":"4401_CR132","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/10499091241280610","volume":"42","author":"JY Kim","year":"2025","unstructured":"Kim JY, Dalton JC, Cort N, Herndon JE 2nd, Affronti ML, Peters KB, et al. Comparing knowledge and perceptions of palliative care among Neuro-Oncology patients, caregivers, and providers to a representative U.S. sample. Am J Hosp Palliat Care. 2025;42(9):862\u20138. https:\/\/doi.org\/10.1177\/10499091241280610.","journal-title":"Am J Hosp Palliat Care"},{"issue":"10","key":"4401_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102567","volume":"14","author":"MC Jin","year":"2022","unstructured":"Jin MC, Hsin G, Ratliff J, Thomas R, Zygourakis CC, Li G, et al. Modifiers of and disparities in palliative and supportive care timing and utilization among neurosurgical patients with malignant central nervous system tumors. Cancers (Basel). 2022;14(10):2567. https:\/\/doi.org\/10.3390\/cancers14102567.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4401_CR134","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013440.pub2","volume":"1","author":"A Byrne","year":"2022","unstructured":"Byrne A, Torrens-Burton A, Sivell S, Moraes FY, Bulbeck H, Bernstein M, et al. Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers. Cochrane Database Syst Rev. 2022;1(1):CD013440. https:\/\/doi.org\/10.1002\/14651858.CD013440.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"4401_CR135","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.wneu.2024.09.125","volume":"192","author":"II Okon","year":"2024","unstructured":"Okon II, Osama M, Akpan A, Fabrini Paleare LF, Ferreira MY, Shafqat MD, et al. The evolving role of palliative care in older people with glioblastoma. World Neurosurg. 2024;192:140\u20139. https:\/\/doi.org\/10.1016\/j.wneu.2024.09.125.","journal-title":"World Neurosurg"},{"issue":"5","key":"4401_CR136","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/nop\/npae052","volume":"11","author":"L Salmi","year":"2024","unstructured":"Salmi L, Otis-Green S, Hayden A, Taylor LP, Reblin M, Kwan BM. Identifying research priorities and essential elements of palliative care services for people facing malignant brain tumors: a participatory co-design approach. Neurooncol Pract. 2024;11(5):556\u201365. https:\/\/doi.org\/10.1093\/nop\/npae052.","journal-title":"Neurooncol Pract"},{"issue":"1","key":"4401_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-023-01154-z","volume":"22","author":"NS N\u00e5hls","year":"2023","unstructured":"N\u00e5hls NS, Leskel\u00e4 RL, Saarto T, Hirvonen O, Anttonen A. Effect of palliative care decisions making on hospital service use at end-of-life in patients with malignant brain tumors: a retrospective study. BMC Palliat Care. 2023;22(1):39. https:\/\/doi.org\/10.1186\/s12904-023-01154-z.","journal-title":"BMC Palliat Care"},{"issue":"1","key":"4401_CR138","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf064","volume":"7","author":"M Fabbro","year":"2025","unstructured":"Fabbro M, Thomaso M, Darlix A, Perotin V, Gallay C, Charissoux M, et al. Integrated early palliative care for patients with newly diagnosed glioblastoma: the GLIOSUPPORT feasibility study. Neuro-Oncol Adv. 2025;7(1):vdaf064. https:\/\/doi.org\/10.1093\/noajnl\/vdaf064.","journal-title":"Neuro-Oncol Adv"},{"key":"4401_CR139","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076625","volume":"384","author":"ECT Geijteman","year":"2024","unstructured":"Geijteman ECT, Kuip EJM, Oskam J, Lees D, Bruera E. Illness trajectories of incurable solid cancers. BMJ. 2024;384:e076625. https:\/\/doi.org\/10.1136\/bmj-2023-076625.","journal-title":"BMJ"},{"issue":"4","key":"4401_CR140","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.gerinurse.2016.03.001","volume":"37","author":"JL Pan","year":"2016","unstructured":"Pan JL, Chochinov H, Thompson G, McClement S. The TIME Questionnaire: a tool for eliciting personhood and enhancing dignity in nursing homes. Geriatr Nurs. 2016;37(4):273\u20137. https:\/\/doi.org\/10.1016\/j.gerinurse.2016.03.001.","journal-title":"Geriatr Nurs"},{"issue":"7","key":"4401_CR141","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-013-0359-y","volume":"13","author":"L Dirven","year":"2013","unstructured":"Dirven L, Reijneveld JC, Aaronson NK, Bottomley A, Uitdehaag BM, Taphoorn MJ. Health-related quality of life in patients with brain tumors: limitations and additional outcome measures. Curr Neurol Neurosci Rep. 2013;13(7):359. https:\/\/doi.org\/10.1007\/s11910-013-0359-y.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"4401_CR142","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/nop\/npae022","volume":"11","author":"RC Crooms","year":"2024","unstructured":"Crooms RC, Nnemnbeng JF, Taylor JW, Goldstein NE, Gorbenko K, Vickrey BG. Clinician perspectives on integrating neuro-oncology and palliative care for patients with high-grade glioma. Neurooncol Pract. 2024;11(4):404\u201312. https:\/\/doi.org\/10.1093\/nop\/npae022. (PMID: 39006519; PMCID: PMC11241354).","journal-title":"Neurooncol Pract"},{"key":"4401_CR143","unstructured":"National Institute for Health and Care Excellence (NICE). End-of-life care for adults: service delivery. Available at: https:\/\/www.nice.org.uk\/guidance\/ng142. Accessed: 10th Dec, 2025"},{"key":"4401_CR144","unstructured":"Plan de Cuidados Paliativos de Castilla y Le\u00f3n 2017\u20132020. Junta de Castilla y Le\u00f3n; 2017. Available at: https:\/\/www.saludcastillayleon.es\/profesionales\/es\/cuidados-paliativos\/plan-cuidados-paliativos-castilla-leon.ficheros\/1119095-cuidados%20paliativos%20%28FINAL%20NAVEGABLE%29.pdf. Accessed: 10th Dec, 2025"},{"key":"4401_CR145","unstructured":"Cuidados Paliativos. Gu\u00eda para Atenci\u00f3n Primaria. Ministerio de Sanidad; 2021. Available at: https:\/\/www.google.es\/url?esrc=s&q=&rct=j&sa=U&url=https:\/\/ingesa.sanidad.gob.es\/dam\/jcr:cf884739-e43c-4a8e-87e6-4a3c226acc0b\/Cuidados_Paliativos.pdf&ved=2ahUKEwioyP_P37ORAxXm_7sIHVmbPLYQFnoECAYQAg&usg=AOvVaw3HHgCmXP4e0t5BJKhxanhN. Accessed: 10th Dec, 2025"},{"key":"4401_CR146","unstructured":"Ben\u00edtez-Rosario MA, Alonso Babarro A, Gonz\u00e1lez Guillermo T. Protocolo de Tratamiento en Cuidados Paliativos. SECPAL, 2023. Available at: https:\/\/www.secpal.org\/wp-content\/uploads\/2024\/05\/protocolos-de-tratamiento-en-cuidados-paliativos-2023.pdf. Accessed: 10th Dec, 2025."},{"issue":"7","key":"4401_CR147","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/0269216309107024","volume":"23","author":"NI Cherny","year":"2009","unstructured":"Cherny NI, Radbruch L, Board of the European Association for Palliative Care. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med. 2009;23(7):581\u201393. https:\/\/doi.org\/10.1177\/0269216309107024.","journal-title":"Palliat Med"},{"issue":"7","key":"4401_CR148","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/annonc\/mdp048","volume":"20","author":"M Maltoni","year":"2009","unstructured":"Maltoni M, Pittureri C, Scarpi E, Piccinini L, Martini F, Turci P, et al. Palliative sedation therapy does not hasten death: results from a prospective multicenter study. Ann Oncol. 2009;20(7):1163\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdp048.","journal-title":"Ann Oncol"},{"key":"4401_CR149","unstructured":"Ley 41\/2002, b\u00e1sica reguladora de la autonom\u00eda del paciente. BOE n\u00fam. 274; 2002. Available at: https:\/\/www.boe.es\/buscar\/act.php?id=BOE-A-2002-22188. Accessed: 10th Dec, 2025"},{"key":"4401_CR150","unstructured":"Ley 4\/2017, de 9 de marzo, de Derechos y Garant\u00edas en el Proceso de Morir (Madrid). Available at: https:\/\/www.boe.es\/buscar\/doc.php?id=BOE-A-2017-7178. Accessed: 10th Dec, 2025"},{"key":"4401_CR151","unstructured":"Ley 16\/2018, de 28 de junio, de derechos y garant\u00edas de la dignidad de la persona en el proceso de atenci\u00f3n al final de la vida (Comunidad de Valencia). Available at: https:\/\/www.boe.es\/buscar\/act.php?id=BOE-A-2018-10760. Accessed: 4th Dec, 2025."},{"key":"4401_CR152","unstructured":"Ley Org\u00e1nica 3\/2021, de 24 de marzo, de regulaci\u00f3n de la eutanasia. BOE n\u00fam. 72; 2021. Available at: https:\/\/www.boe.es\/buscar\/act.php?id=BOE-A-2021-4628. Accessed: 4th Dec, 2025."},{"key":"4401_CR153","unstructured":"DECRETO 23\/2024, de 21 de noviembre, por el que se regula el procedimiento de formalizaci\u00f3n de instrucciones previas en el \u00e1mbito sanitario y la organizaci\u00f3n y el funcionamiento del Registro de Instrucciones Previas de Castilla y Le\u00f3n. Available at: https:\/\/bocyl.jcyl.es\/eli\/es-cl\/d\/2024\/11\/21\/23\/. Accessed: 4th Dec, 2025."},{"key":"4401_CR154","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Defunciones seg\u00fan la causa de muerte 2022. Available at: https:\/\/www.ine.es\/prensa\/edcm_2022.pdf. Accessed: 4th Dec, 2025."}],"updated-by":[{"DOI":"10.1007\/s12094-026-04481-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000}}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04401-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04401-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04401-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:01:38Z","timestamp":1792803698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04401-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":154,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["4401"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04401-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: to correct the author names Mar\u00eda Hern\u00e1ndez Miguel and Ana Mar\u00eda Ruiz Moreno.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12094-026-04481-8","URL":"https:\/\/doi.org\/10.1007\/s12094-026-04481-8","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflicts of interest regarding the composition of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review article is based on previously published studies and does not involve new studies with human participants or animals conducted by any of the authors. Hence, ethical approval and informed consent were not applicable.","order":2,"name":"Ethics","label":"Ethical statements","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent is not needed for this review article.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No patients or animals were used for the composition of this paper.","order":4,"name":"Ethics","label":"Research involving human participants and\/or animals","group":{"name":"EthicsHeading","label":"Declarations"}}]}}